Interpreting overall survival results when progression-free survival benefits exist in today's oncology landscape: a metastatic renal cell carcinoma case study

Interpreting overall survival results when progression-free survival benefits exist in today's oncology landscape: a metastatic renal cell carcinoma case study

Yiyun Tang,1 Paul Bycott,1 Örjan Åkerborg,2 Linus Jönsson,2 Sylvie Negrier,3 Connie Chen4 1Pfizer Global Research and Development, La Jolla, CA, USA; 2OptumInsight, Stockholm, Sweden; 3Medical Oncology Department, University of Lyon, Lyon, France; 4Pfizer Global Outcomes...

Full description

Bibliographic Details
Main Authors: Tang Y, Bycott P, Åkerborg Ö, Jönsson L, Negrier S, Chen C
Format: Article
Language:English
Published: Dove Medical Press 2014-09-01
Series:Cancer Management and Research
Online Access:http://www.dovepress.com/interpreting-overall-survival-results-when-progression-free-survival-b-peer-reviewed-article-CMAR

Internet

http://www.dovepress.com/interpreting-overall-survival-results-when-progression-free-survival-b-peer-reviewed-article-CMAR

Similar Items